PriceTargets.com logo

MetaVia - MTVA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 697.34%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.51 As of 03/13/2025 04:56 PM ET
▲ +0.0056 (0.37%)

This chart shows the closing price for MTVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MetaVia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MTVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MTVA

Analyst Price Target is $12.00
▲ +697.34% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for MetaVia in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 697.34% upside from the last price of $1.51.

This chart shows the closing price for MTVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in MetaVia.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/14/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/14/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/30/2024HC WainwrightInitiated CoverageBuy$12.00
(Data available from 3/14/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/14/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/14/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/13/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/13/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/12/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/11/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/13/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.
Read More

Today's Range

Now: $1.51
Low: $1.49
High: $1.56

50 Day Range

MA: $1.78
Low: $1.45
High: $2.49

52 Week Range

Now: $1.51
Low: $1.29
High: $5.30

Volume

6,636 shs

Average Volume

39,303 shs

Market Capitalization

$12.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27

Frequently Asked Questions

What sell-side analysts currently cover shares of MetaVia?

The following Wall Street analysts have issued reports on MetaVia in the last year: HC Wainwright.
View the latest analyst ratings for MTVA.

What is the current price target for MetaVia?

0 Wall Street analysts have set twelve-month price targets for MetaVia in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 697.3%. HC Wainwright has the highest price target set, predicting MTVA will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $12.00 for MetaVia in the next year.
View the latest price targets for MTVA.

What is the current consensus analyst rating for MetaVia?

MetaVia currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MTVA will outperform the market and that investors should add to their positions of MetaVia.
View the latest ratings for MTVA.

What other companies compete with MetaVia?

Other companies that are similar to MetaVia include Repare Therapeutics, CytomX Therapeutics, Outlook Therapeutics, AlloVir and Aadi Bioscience. Learn More about companies similar to MetaVia.

How do I contact MetaVia's investor relations team?

MetaVia's physical mailing address is 545 Concord Avenue Suite 210, Cambridge MA, 02138. The company's listed phone number is 857-702-9600 and its investor relations email address is ir@neurobopharma.com. The official website for MetaVia is www.neurobopharma.com. Learn More about contacing MetaVia investor relations.